TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

Brief description of study

Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and HIF activation. We hypothesize that blocking autophagy and the VEGF pathway will improve both response and PFS following TACE.

The target population are those patients with liver-only or liver-dominant metastatic colorectal cancer failing at least one line of systemic chemotherapy due to progression or toxicity.

Subjects will be recruited from the Gastrointestinal and Interventional Oncology Clinics at the University of Pennsylvania Abramson Cancer Center

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Metastatic Adenocarcinoma,colon,rectum,cancer
Age: Between 18 Years - 99 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 848444

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).